2. Academic Validation
  3. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

  • Nat Commun. 2024 Jan 10;15(1):446. doi: 10.1038/s41467-024-44703-7.
Kristina Maas-Bauer # 1,  Anna-Verena Stell # 1,  Kai-Li Yan # 1,  Enrique de Vega # 1 2,  Janaki Manoja Vinnakota # 1,  Susanne Unger 3,  Nicolas Núñez 3,  Johana Norona 1,  Nana Talvard-Balland 1,  Stefanie Koßmann 1,  Carsten Schwan 4,  Cornelius Miething 1,  Uta S Martens 1 4,  Khalid Shoumariyeh 1 5,  Rosa P Nestor 1,  Sandra Duquesne 1,  Kathrin Hanke 1,  Michal Rackiewicz 6 7,  Zehan Hu 6 7,  Nadia El Khawanky 1,  Sanaz Taromi 1,  Hana Andrlova 1,  Hemin Faraidun 2,  Stefanie Walter 1,  Dietmar Pfeifer 1,  Marie Follo 1,  Johannes Waldschmidt 1,  Wolfgang Melchinger 1,  Michael Rassner 1,  Claudia Wehr 1,  Annette Schmitt-Graeff 8,  Sebastian Halbach 5 9,  James Liao 10,  Georg Häcker 11,  Tilman Brummer 5 9 12,  Joern Dengjel 6 7,  Geoffroy Andrieux 13,  Robert Grosse 4 14,  Sonia Tugues 3,  Bruce R Blazar 15,  Burkhard Becher 3,  Melanie Boerries 5 13,  Robert Zeiser 16 17 18
Affiliations

Affiliations

  • 1 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • 2 Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • 3 Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • 4 Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty, University of Freiburg, Freiburg, Germany.
  • 5 German Cancer Consortium (DKTK), Partner Site Freiburg, a partnership between German Cancer Research Center (DKFZ) and Medical Center - University of Freiburg, Freiburg, Germany.
  • 6 Department of Biology, University of Fribourg, Fribourg, Switzerland.
  • 7 Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany.
  • 8 Institute of Pathology, University Hospital Freiburg, Freiburg, Germany.
  • 9 IMMZ, University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • 10 Department of Medicine, University of Arizona, Tucson, USA.
  • 11 IMMH, University Hospital Freiburg, Faculty of Medicine, Freiburg, Germany.
  • 12 Signaling Research Centres BIOSS and CIBSS - Centre for Integrative Biological Signaling Studies, University of Freiburg, Freiburg, Germany.
  • 13 Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • 14 CIBSS-Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany.
  • 15 Department of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, USA.
  • 16 Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. robert.zeiser@uniklinik-freiburg.de.
  • 17 German Cancer Consortium (DKTK), Partner Site Freiburg, a partnership between German Cancer Research Center (DKFZ) and Medical Center - University of Freiburg, Freiburg, Germany. robert.zeiser@uniklinik-freiburg.de.
  • 18 Signaling Research Centres BIOSS and CIBSS - Centre for Integrative Biological Signaling Studies, University of Freiburg, Freiburg, Germany. robert.zeiser@uniklinik-freiburg.de.
  • # Contributed equally.
PMID: 38199985 DOI: 10.1038/s41467-024-44703-7
Abstract

Patients with corticosteroid-refractory acute graft-versus-host disease (aGVHD) have a low one-year survival rate. Identification and validation of novel targetable kinases in patients who experience corticosteroid-refractory-aGVHD may help improve outcomes. Kinase-specific proteomics of leukocytes from patients with corticosteroid-refractory-GVHD identified rho kinase type 1 (ROCK1) as the most significantly upregulated kinase. ROCK1/2 inhibition improved survival and histological GVHD severity in mice and was synergistic with JAK1/2 inhibition, without compromising graft-versus-leukemia-effects. ROCK1/2-inhibition in macrophages or dendritic cells prior to transfer reduced GVHD severity. Mechanistically, ROCK1/2 inhibition or ROCK1 knockdown interfered with CD80, CD86, MHC-II expression and IL-6, IL-1β, iNOS and TNF production in myeloid cells. This was accompanied by impaired T cell activation by dendritic cells and inhibition of cytoskeletal rearrangements, thereby reducing macrophage and DC migration. NF-κB signaling was reduced in myeloid cells following ROCK1/2 inhibition. In conclusion, ROCK1/2 inhibition interferes with immune activation at multiple levels and reduces acute GVHD while maintaining GVL-effects, including in corticosteroid-refractory settings.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z